Neurodevelopmental outcomes and in-utero antiretroviral exposure in HIV-exposed uninfected children

• Published in: AIDS (London) Vol. 32; no. 17; pp. 2583 - 2592
• Main Authors: Piske, Micah, Budd, Matthew A, Qiu, Annie Q, Maan, Evelyn J, Sauvé, Laura J, Forbes, John C, Alimenti, Ariane, Janssen, Patricia, Côté, Hélène C.F
• Format: Journal Article
• Language: English
• Published: England Copyright Wolters Kluwer Health, Inc 13.11.2018
• Subjects: AIDS/HIV
• ISSN: 0269-9370; 1473-5571
• DOI: 10.1097/QAD.0000000000001985

OBJECTIVES:To assess and compare neurodevelopmental disorders in HIV-exposed uninfected (HEU) and HIV-unexposed uninfected (HUU) children in British Columbia, Canada. To determine associations between these outcomes and in-utero exposure to antiretroviral drugs. DESIGN:Retrospective controlled cohort study. METHODS:Data were collected on 446 HEU children and 1323 HUU children (matched ∼1 : 3 for age, sex, and geocode) born between 1990 and 2012. Multivariable logistic regressions determined odds ratios of neurodevelopmental disorder diagnoses. RESULTS:HEUs had three times higher odds of being born preterm (P < 0.0001), and a more than two-fold increase in odds for autism, disturbance of emotions, hyperkinetic syndrome, and developmental delay compared with matched HUUs (P < 0.02) in unadjusted analysis. This association was reduced [adjusted neurodevelopmental disorder odds ratio (AOR) = 1.67; 95% confidence interval1.12–2.48; P = 0.011] after adjusting for maternal substance use and/or smoking (children born after April 2000). Regardless of antiretroviral exposure type (i.e. none, treatment with one or multiple drug classes), HEUs had higher odds of any neurodevelopmental disorders compared with matched HUUs; however, there was no evidence suggesting any specific classes of antiretroviral drugs or exposure durations increased their likelihood of neurodevelopmental disorders. CONCLUSION:The results suggest no adverse associations between antiretroviral drugs and neurodevelopmental disorders within antiretroviral-exposed HEU children in our cohort. Prevalence of neurodevelopmental disorders is higher in HEUs; however, maternal substance use plays a role, as could other environmental factors not captured. These findings highlight a need for holistic support for pregnant women as well as careful developmental monitoring of HEUs past infancy, and access to early interventions, particularly among those born preterm and those exposed to addictive substances.